Research programme: enzyme-based Coeliac disease therapeutic - AMYRA BiotechAlternative Names: Gluten-targeting enzymes - AMYRA
Latest Information Update: 23 Apr 2014
At a glance
- Originator AMYRA Biotech AG
- Class Enzymes
- Mechanism of Action Enzyme replacements; Gluten inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Research Coeliac disease
Most Recent Events
- 10 Apr 2014 Early research in Coeliac disease in Switzerland (PO)